For research use only
| Cat No. | ABC-TC0431 |
| Product Type | Human Colon Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Rectum |
| Disease | Rectal Adenocarinoma |
| Product Code | HT55 |
HT-55 colon cancer cells from rectal adenocarcinoma show well-differentiated morphology, key colorectal mutations, useful for pathogenesis and therapy.
The HT-55 is a human colon cancer cell line derived from the rectum of a 54-year-old white female patient with rectal adenocarcinoma. The cells display well-differentiated cancer morphology and grow in adherent clumps that resemble columnar epithelium with a clear border. These clumps show an island growth pattern, forming multiple layers at the center. HT-55 cells retain certain intestinal epithelial functional characteristics, including the expression of epithelial cell polarity-related proteins, but their specific secretory functions have not yet been fully elucidated. As a rectal adenocarcinoma model, this cell carries multiple colorectal cancer characteristic gene mutations: APC gene (p.Gln1131Ter, p.Gln1303Ter, p.Arg1463Ser), TP53 gene (p.Arg213Leu), BRAF gene (p.Asn581Tyr) and DNMT3A gene (p.Lys241Ter), etc. These mutation spectra make it an ideal model for studying the pathogenesis and targeted therapy of colorectal cancer.
| Product Code | HT55 |
| Species | Human |
| Cat.No | ABC-TC0431 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Rectum |
| Disease | Rectal Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Colon Cancer Cell Lines |
HT-55 is a valuable model for studying potential therapies for human rectal cancer. In studies involving HT-55, cell proliferation and death can be affected by anti-cancer drugs through the ERK 1/2, p38-MAPK, and PI3K/AKT pathways of ERK 1/2, p38-MARK, and PI3K/AKT. Further investigation can explore the utilization of existing anti-cancer therapy targeting these pathways in HT-55. Moreover, a BRAF mutation (N581Y) has been detected in HT-55, indicating that HT-55 can help improve strategies combining anti-EGFR monoclonal antibodies with BRAF inhibitors for BRAF mutant cancers to elucidate the molecular pathogenesis of colorectal cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
